BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 10626362)

  • 21. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
    Holford J; Beale PJ; Boxall FE; Sharp SY; Kelland LR
    Eur J Cancer; 2000 Oct; 36(15):1984-90. PubMed ID: 11000581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.
    Komeda S; Kalayda GV; Lutz M; Spek AL; Yamanaka Y; Sato T; Chikuma M; Reedijk J
    J Med Chem; 2003 Mar; 46(7):1210-9. PubMed ID: 12646031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
    Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
    J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel bis-platinum complexes endowed with an improved pharmacological profile.
    Gatti L; Perego P; Leone R; Apostoli P; Carenini N; Corna E; Allievi C; Bastrup U; De Munari S; Di Giovine S; Nicoli P; Grugni M; Natangelo M; Pardi G; Pezzoni G; Singer JW; Zunino F
    Mol Pharm; 2010 Feb; 7(1):207-16. PubMed ID: 19919086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular processing of platinum anticancer drugs.
    Wang D; Lippard SJ
    Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents.
    Keter FK; Kanyanda S; Lyantagaye SS; Darkwa J; Rees DJ; Meyer M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):127-38. PubMed ID: 18350297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three new asymmetric trans-amine(azole)dichloridoplatinum complexes that overcome cisplatin resistance and their reactions with 5'-GMP.
    Pantoja E; Gallipoli A; van Zutphen S; Komeda S; Reddy D; Jaganyi D; Lutz M; Tooke DM; Spek AL; Navarro-Ranninger C; Reedijk J
    J Inorg Biochem; 2006 Dec; 100(12):1955-64. PubMed ID: 17083978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New synthetic route to [bis-1,2-(aminomethyl)benzene]dichloroplatinum(II) complexes, screening for cytotoxic activity in cisplatin-sensitive and resistant human cancer cell lines, and reaction with glutathione.
    Rinke K; Grünert R; Bednarski PJ
    Pharmazie; 2001 Oct; 56(10):763-9. PubMed ID: 11683118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
    Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
    J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review.
    Ferguson PJ
    J Otolaryngol; 1995 Aug; 24(4):242-52. PubMed ID: 8551538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinatorial discovery of new asymmetric cis platinum anticancer complexes is made possible with solid-phase synthetic methods.
    van Zutphen S; Stone EA; van Rijt S; Robillard MS; van der Marel GA; Overkleeft HS; den Dulk H; Brouwer J; Reedijk J
    J Inorg Biochem; 2005 Oct; 99(10):2032-8. PubMed ID: 16099049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.